Viracta

Viracta is a startup based in Israel. Brouky classifies it under Healthcare & Life Sciences.

Viracta develops precision oncology therapies for virally associated cancers, using its investigational drug Natinostat to induce Epstein–Barr virus gene expression which, in combination with antiviral valganciclovir, leads to targeted cancer cell death. The treatment is currently being tested in clinical studies for EBV-positive lymphomas and solid tumors.